Stem cell treatments could come by 2005

韩雪娜

日期: 2002-10-25 今日/总浏览: 1/1562( X7 _! f" x- Z1 s. c! g
3 |$ ?6 m: W* x3 p2 o8 f3 ?' t
9 ]' t" L/ f7 L( ]* T+ L% d
% T' f) a1 q& S' a' \( o* R/ U" f

+ x% q9 r& p5 b7 K* M, AThefirstcommerciallyavailablestemcell-derivedproductslikelywillcomefromadultstemcellsandbeforthetreatmentofneurologicaldisorderssuchasParkinson'sandAlzheimer'sdisease,theheadofanadultstemcellcompanytoldUnitedPressInternational.
( b7 h/ h* y) T1 z' c4 ~/ P% P+ fTheproductscouldbeavailableinthenextthreeyears,saidMartinMcGlynn,presidentandchiefexecutiveofficerofStemCellsInc.,ofPaloAlto,Calif.,whichisworkingtodevelopmedicaltreatmentsderivedfromadultstemcells.McGlynnwasexpectedtomakesimilarremarksatTechvest's4thAnnualHealthcareConference&ExpoinBostonWednesday.
' Z, U2 p% k$ D. V+ \$ G! R+ B+ w( zStemcellshavetheabilitytogiverisetodifferentcelltypesinthebody.Theyhavethepotentialtoreplacetissuesdamagedbydisease.
" K/ n( q5 U6 V. q) _8 A+ ZEmbryonicstemcellscangiverisetoanycelltypeandthushavethegreatestpotentialtotreatthewidestrangeofdiseases.However,theyarecontroversialbecauseharvestingthemrequiresthedestructionofembryos.Adultstemcells,whichcanbederivedfromadulttissueswithoutharmingthedonor,offeralesscontroversialalternative,althoughtheycangiveriseonlytoalimitednumberofcelltypes.+ |/ |" \; C6 c4 @
Mypredictionisthat...we'relikelytoseeoneortwostemcellproductsonthemarketinthisdecade,McGlynnsaid.Productsderivedfromadultstemcellsarelikelytobethefirstproductsbecausethesearefurtheralonginthedevelopmentprocessanddon'thavealltheregulatoryhurdlesthatareassociatedwithembryonicstemcells,hesaid.3 P2 W8 g0 M( P: \! _2 l
Suchproductsprobablywillappearonthemarketstartingfromaround2005andcontinuinginthebackhalfofthisdecade,hesaid.
, c3 e, F& n5 E# g3 \7 n% wMcGlynnpredictedthefirstproductswouldbetreatmentsfordegenerativediseasesofthecentralnervoussystem,includingParkinson's,Alzheimer's,strokeandparalysis.
- N& H" g  y* yIwouldagreewith(McGlynn)thatsomeoftheearliestproductstoreachcommercializationwillbeforneurologicaldisorders,LindaPowers,managingdirectorofToucanCapital,aventurecapitalfirminBethesda,Md.,toldUPI.It'sstillupintheairwhether(thefirstproducts)willbeadultorembryonicstemcells,addedPowers,whosefirmhasmadeinvestmentsinbothadultandembryonicstemcellcompanies.% U; T% N3 m) U. B0 u; w( {
Wereallyarelookingacrosstheboardatadultandembryonicstemcells,Powerssaid.We'renottiltingonewayortheother.Wewanttoseewhatlookslikeitproducesthebestresultsandgofromthere.It'stooearlytotellwhichlineofcellswillbethefirsttoreachthemarket,sheadded.
# V" _$ z; F0 m- yMcGlynnsaidheexpectsembryonicstemcellseventuallytobecommercializedaswell.Subjecttotheavailabilityofcapital,Iwouldanticipateembryonicstemcellsciencewillcontinuetobeworkedonandimproved,hesaid.Overtime,scientistsmightlearnhowtofullyunlockthepotentialofembryonicstemcellsanddevelopthemasdiseasetreatments,hesaid.
. ^1 ^9 |2 j  G' N$ n0 [2 [: QDependingoneconomicsandthedisease-treatingcapabilityofeachcellline,McGlynnadded,Wecouldhaveboth(adultandembryonicstemcell-derivedproducts)outthereonthemarket.
9 ?, k2 u& n! H& M* j; o1 P
: D/ X  \9 u, O3 |/ z' m  X. b# U: X. Y- g! \; N
7 i- r; d' B# w! s; _$ R
0 k1 z. S2 U% G5 \' c! e9 i
& C/ y& {* E# W& y8 n/ p
作者: Steve Mitchell2 L  D% g) k$ s  R- l
来源: UPI Medical Correspondent! W, B: _: ^9 z
发布者: 刘斌